XML 24 R13.htm IDEA: XBRL DOCUMENT
v3.20.2

Note 5 - Goodwill and Intangible Assets, Net | 6 Months Ended
--- | ---
Sep. 30, 2020
Notes to Financial Statements |
Goodwill and Intangible Assets Disclosure [Text Block] | Note 5. Goodwill and Intangible Assets, Net Finite-lived intangible assets consist of the following:
|  | September 30, 2020 |  |  | March 31, 2020 |
|  | Gross Carrying Amount |  |  | Accumulated Amortization |  |  | Net Carrying Amount |  |  | Gross Carrying Amount |  |  | Accumulated Amortization |  |  | Net Carrying Amount |
Intellectual property |  | $ | 20,852 |  |  | $ | (7,671 | ) |  | $ | 13,181 |  |  | $ | 15,731 |  |  | $ | (6,454 | ) |  | $ | 9,277 |
Trade names |  |  | 8,477 |  |  |  | (2,992 | ) |  |  | 5,485 |  |  |  | 5,839 |  |  |  | (2,855 | ) |  |  | 2,984 |
Customer relationships |  |  | 143,378 |  |  |  | (45,464 | ) |  |  | 97,914 |  |  |  | 146,106 |  |  |  | (38,777 | ) |  |  | 107,329 |
Non-compete agreements |  |  | 1,299 |  |  |  | (1,176 | ) |  |  | 123 |  |  |  | 1,447 |  |  |  | (1,166 | ) |  |  | 281 |
Total |  | $ | 174,006 |  |  | $ | (57,303 | ) |  | $ | 116,703 |  |  | $ | 169,123 |  |  | $ | (49,252 | ) |  | $ | 119,871 |
Amortization expense for finite-lived intangible assets acquired in a business combination was $3,512 and $6,866 for the three and six months ended September 30, 2020 and $1,658 and $3,330 for the three and six months ended September 30, 2019, respectively. The increase in the amortization expense was attributable to intangible assets acquired as part of the GPT acquisition, including a cumulative effect true up that we recorded during the three months ended June 30, 2020 as we made adjustments to purchase accounting, see Note 12. "Significant Transactions." The following is estimated amortization expense for the years ending March 31:
2021 |  | $ | 14,635 |
2022 |  |  | 14,599 |
2023 |  |  | 14,581 |
2024 |  |  | 14,056 |
2025 |  |  | 12,471 |
The change in the carrying amount of goodwill was as follows:
|  | Sterilization and Disinfection Control |  |  | Instruments |  |  | Biopharmaceutical Development |  |  | Continuous Monitoring |  |  | Corporate and Other |  |  | Total |
March 31, 2020 |  | $ | 29,594 |  |  | $ | 19,123 |  |  | $ | 74,716 |  |  | $ | 18,103 |  |  | $ | - |  |  | $ | 141,536 |
Effect of foreign currency translation |  |  | 500 |  |  |  | 60 |  |  |  | 8,604 |  |  |  | - |  |  |  | - |  |  |  | 9,164 |
Goodwill adjustment related to GPT acquisition |  |  | - |  |  |  | - |  |  |  | 5,665 |  |  |  | - |  |  |  | - |  |  |  | 5,665 |
September 30, 2020 |  | $ | 30,094 |  |  | $ | 19,183 |  |  | $ | 88,985 |  |  | $ | 18,103 |  |  | $ | - |  |  | $ | 156,365 |

X
- References No definition available. + Details
Name: | us-gaap_DisclosureTextBlockAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The entire disclosure for goodwill and intangible assets. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 350 -URI http://asc.fasb.org/topic&trid=2144416 + Details
Name: | us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock
Namespace Prefix: | us-gaap_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration